Nice catch, Nuke (8-pt vs. 10-pt Cotara interim data). Recall, Joe Shan (VP Clinical & Reg. Affairs) said this about the India Cotara/Brain Ph.2 trial in the 7-14-09 CC:
Joe Shan 7-14-09: “We’re also continuing to make progress in the ongoing Ph.2 Cotara GBM study [India]. As noted in our last call, we have taken measures to maximize trial efficiency while reducing overall program spending by focusing on the top-performing centers. Although enrollment remains slower than we’d like, we’ve now successfully passed the halfway mark in patient enrollment [ 40/2 = 20 – see http://clinicaltrials.gov/ct2/show/NCT00677716 ] while significantly cutting costs. This strategy allows us to keep these studies active in order to continue generating valuable clinical data for the Cotara program, and as addl. resources become available or with the help of a development partner, the Ph.2 study can be quickly expanded towards completion. Based on the data generated to date, both we and our clinical investigators continue to believe in Cotara’s tremendous potential for the treatment of this deadly brain cancer.” http://tinyurl.com/nt4zql
News 
Market Data 
Discover 
